Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

J Hippisley-Cox, D Young, C Coupland, KM Channon… - Heart, 2020 - heart.bmj.com
Background There is uncertainty about the associations of angiotensive enzyme (ACE)
inhibitor and angiotensin receptor blocker (ARB) drugs with COVID-19 disease. We studied …

Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)

N Mehta, A Kalra, AS Nowacki, S Anjewierden… - JAMA …, 2020 - jamanetwork.com
Importance The role of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II
receptor blockers (ARB) in the setting of the coronavirus disease 2019 (COVID-19) …

Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality

EL Fosbøl, JH Butt, L Østergaard, C Andersson… - Jama, 2020 - jamanetwork.com
Importance It has been hypothesized that angiotensin-converting enzyme inhibitors
(ACEIs)/angiotensin receptor blockers (ARBs) may make patients more susceptible to …

Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis

DR Morales, MM Conover, SC You, N Pratt… - The Lancet Digital …, 2021 - thelancet.com
Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) have been postulated to affect susceptibility to COVID-19. Observational …

Cardiovascular disease, drug therapy, and mortality in Covid-19

MR Mehra, SS Desai, SR Kuy, TD Henry… - New England Journal …, 2020 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) may disproportionately affect
people with cardiovascular disease. Concern has been aroused regarding a potential …

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis

ME Flacco, CA Martellucci, F Bravi, G Parruti… - Heart, 2020 - heart.bmj.com
Objective It has been hypothesised that the use of ACE inhibitors and angiotensin receptor
blockers (ARBs) might either increase or reduce the risk of severe or lethal COVID-19. The …

ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis

X Zhang, J Yu, L Pan, H Jiang - Pharmacological research, 2020 - Elsevier
The effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) on the risk of COVID-19 infection and disease progression are yet to be …

A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor …

A Grover, M Oberoi - European Heart Journal-Cardiovascular …, 2021 - academic.oup.com
Introduction Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) share their target receptor site with the SARS-CoV-2 virus, that may cause …

[PDF][PDF] Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19

N Şenkal, R Meral, A Medetalibeyoğlu… - Anatol J …, 2020 - jag.journalagent.com
Objective: Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). Renin-angiotensin-aldosterone-system (RAAS) …

Renin–angiotensin–aldosterone system blockers and the risk of Covid-19

G Mancia, F Rea, M Ludergnani… - New England Journal …, 2020 - Mass Medical Soc
Background A potential association between the use of angiotensin-receptor blockers
(ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus …